Two-probe heat treatment for cervical precancer in women with HIV
Tests heat treatment with one or two probes for cervical precancer in women with HIV.
Key facts
- Who runs it
- Fred Hutchinson Cancer Center
- Where
- Durban, South AfricaSee the site
- Trial code
- Registry title
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 15 Oct 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Thermal ablation (TA) with 1 probe
- Thermal ablation (TA) with 2 probes
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 25 to 49 who live with HIV and have a positive cervical screening test. It compares treating cervical precancer with one heat probe or two.
- Age
- 25 to 49 years
- Sex
- Women only
- Disease stage
- Positive hrHPV or VIA screening test within 3 months of joining; Type 1 transformation zone (TZ1); able to have thermal ablation
- Earlier treatment
- Must not have had treatment for cervical precancer before
- Biomarker or test result
- Positive hrHPV or VIA test within 3 months of joining
Main reasons for not taking part
- Screened for cervical cancer outside the study in the last 6 months
- Pregnant now or less than 6 weeks after giving birth
- Earlier diagnosis of cervical cancer
- Total hysterectomy
- Currently being treated for any cancer
This trial only enrols participants living with HIV. The registry sentence this rests on: Living with HIV
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- 25-49 years old
- Living with HIV
- Intact cervix
- Willing to return to facility at 6 months
- Willing and able to provide informed consent
- Positive hrHPV or VIA test within 3 months of enrollment
- Type 1 transformation zone (TZ1)
- Thermal ablation eligible
Who cannot take part
- Prior diagnosis of cervical cancer
- Currently receiving treatment for any cancer
- Screened for cervical cancer outside of study in last 6 months
- A history of treatment for cervical precancer
- Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study
- Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled
- Currently pregnant or less than 6 weeks postpartum
- Total hysterectomy
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 25 and 49 years old?
This trial is currently available in South Africa.
- Centre for the AIDS Programme of Research in South AfricaDurban, South AfricaContact: Nivashnee Naicker, MBChB, MAS, MPHTaking people
About the trial
What the trial wants to find out
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.
The 2 groups in the trial
- Group 1 (TA with 1 probe)Treatment being tested
Participants undergo a clinical exam, soft-brush endocervical and ectocervical biopsies, digital imaging, and visual assessment for TA, and if eligible undergo TA with 1 probe at month 0.
Treatment: Thermal ablation (TA) with 1 probe
- Group 2 (TA with 2 probes)Treatment being tested
Participants undergo a clinical exam, soft-brush endocervical and ectocervical biopsies, digital imaging, and visual assessment for TA, and if eligible undergo TA with 2 probes at month 0.
Treatment: Thermal ablation (TA) with 2 probes
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV
- Plain-language title
- Two-probe heat treatment for cervical precancer in women with HIVGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Criteria questions
- Built from NCT07645378, who can take part
- Record updated
- 3 November 2026